$9.150
-0.374 (-4.09%)Zum Schluss
TLX im Vergleich zur Peergroup
In the context of the broader market, TLX competes directly with industry leaders such as KOD and CGON. With a market capitalization of $3.10B, it holds a significant position in the sector. When comparing efficiency, TLX's gross margin of N/A stands against KOD's N/A and CGON's -239.24%. Such benchmarking helps identify whether Telix Pharmaceuticals Limited is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von Telix Pharmaceuticals Ltd
Telix reported Q3 2026 revenue of $245 million, a 19% increase year-over-year, showing strong demand for its products. However, its forward P/E ratio of 140.8451 raises concerns about valuation.
Financials
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.